Aggregate published data suggest that the combination of SGLT2 and RAAS inhibitors in the treatment of patients with T2DM may be similar in efficacy and safety if not superior to SGLT2‐Is alone. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.